Roflumilast foam for seborrheic dermatitis
Part of Skin clinical trials.
This study tests a new foam (roflumilast) applied to the skin to treat seborrheic dermatitis, a condition causing red, flaky patches usually on the scalp or face. It aims to see if the foam reduces redness and scaling better than a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 9 years old.
- You need a confirmed diagnosis of seborrheic dermatitis that has been stable for at least 4 weeks.
- Your skin condition should be moderate or severe (not mild).
- You should be generally healthy, with no serious medical conditions or infections on the treated skin.
- Women who can have children must use reliable birth control and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new lotion for people with mild to moderate seborrheic dermatitis (a common skin condition causing red, scaly patches on the scalp, face, or chest). The study checks safety and how well the lotion works.
This study tests a special cream called TRIDERM D.S. on babies and toddlers (0 to 3 years old) with cradle cap or mild-to-moderate seborrheic dermatitis. The cream aims to normalize the skin and reduce flaking and redness, offering a gentle option for your child's skin.
This trial tests a medicated foam (roflumilast) to relieve skin problems like rash, itching, or eczema that can happen during immune checkpoint inhibitor cancer treatment. The goal is to see if the foam helps clear the skin without needing steroid creams or pills.
This study tests a medicated foam (Roflumilast) in children with non-segmental vitiligo to see if it can improve skin color on the face and body. It is for patients aged 2 to 17 with small patches and at least some pigmented hair in the face patches.
This study tests an oral medicine called roflumilast for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective when taken by mouth, and you can join if you have not used other systemic treatments recently.
This study tests a foam medication (roflumilast 0.3%) applied to the skin to see if it safely reduces hidradenitis suppurativa (HS) bumps and pain in teens and adults. It might help people with mild-to-moderate HS, especially those who haven't tried this foam before.
Hear when a new Seborrheic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.